Fallen off, page-37

Releasing results is not as simple as it sounds. The management are probably in the same position as Abbott and Newman, making absurd promises they could not keep before an election. They probably should not have made promises to release results. One point that is little understood is the biotech companies do not own the results of the trials they pay for. The results are first and foremost the property od the clinical organisation carrying out the trials and the principal investigator at the top of the operation.. They each have their own agendas and can veto any disclosure. There are also matters of intellectual property and further patent opportunities. These opportunities can be ruined by premature disclosure. It is also the case that the main game is presenting to any pharma likely to be in an acceptable deal. This is much more important than shareholders. You have to be in this for the long haul and see any piece weakness as a buying opportunity.